Ignite Creation Date:
2024-05-06 @ 2:11 PM
Last Modification Date:
2024-10-26 @ 1:26 PM
Study NCT ID:
NCT04240002
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2020-01-21
Brief Title:
A Study of Gilteritinib ASP2215 Combined With Chemotherapy in Children Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 FLT3Internal Tandem Duplication ITD Positive Relapsed or Refractory Acute Myeloid Leukemia AML
Sponsor:
Organization:
Astellas Pharma Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
97
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: